Comprehensive analysis for histone acetylation of human colon cancer cells treated with a novel HDAC inhibitor

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1866-1873

  Zhao, Yunlong ^a   Fang, Xiuli ^a   Wang, Ye ^a   Zhang, Junmei ^b   Jiang, Sheng ^c   Liu, Zhe ^d   Ma, Zhenyi ^d   Xu, Liyan ^e   Li, Enmin ^e   Zhang, Kai ^a,d  

^a NANKAI UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

HDACi; Histone; Lysine acetylation; Lysine butyrylation; Post translational modifications (PTMs)

Indexed keywords

DIMETHYL SULFOXIDE; DNA METHYLTRANSFERASE 1; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; LARGAZOLE 7; STABLE ISOTOPE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; LARGAZOLE; THIAZOLE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG DESIGN; EPIGENETICS; GENE OVEREXPRESSION; HCT116 CELL LINE; HETEROCHROMATIN; HISTONE ACETYLATION; HISTONE BUTYRYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PROPIONYLATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE ANALYSIS; STABLE ISOTOPE LABELING BY AMINO ACID; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; ACETYLATION; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY;

ACETYLATION; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DEPSIPEPTIDES; EPIGENESIS, GENETIC; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; ISOTOPE LABELING; THIAZOLES;

EID: 84903717901     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990531     Document Type: Article

References (41)

1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
2. McBain JA, Eastman A, Nobel CS, Mueller GC. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochemical Pharmacol 1997; 53: 1357-68.
3. Shi Y, Sun H, Bao J, et al. Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes. Am J Pathol 2011; 179: 1138-47.
4. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol cellular Biol 1999; 19: 1202-9.
5. Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010; 327: 1000-4.
6. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opinion Genetics Development 1999; 9: 171-4.
7. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
8. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical J 2003; 370: 737-49.
9. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2007; 96 Suppl: R26-30.
10. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-6.
11. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-40.
12. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99.
13. Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 2008; 130: 1806-7.
14. Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 2008; 130: 8455-9.
15. Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 2011; 133: 12474-7.
16. Zeng X, Yin B, Hu Z, et al. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Organic letters 2010; 12: 1368-71.
17. Tan MJ, Luo H, Lee S, et al. Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification. Cell 2011; 146: 1015-27.
18. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
19. Chen Y, Sprung R, Tang Y, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 2007; 6: 812-9.
20. Zhang K, Chen Y, Zhang Z, Zhao Y. Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software. J Proteome Res 2009; 8: 900-6.
21. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-7.
22. Chen Y, Kwon SW, Kim SC, Zhao Y. Integrated approach for manual evaluation of peptides identified by searching protein sequence databases with tandem mass spectra. J Proteome Res 2005; 4: 998-1005.
23. Lee AY, Paweletz CP, Pollock RM, et al. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J Proteome Res 2008; 7: 5177-86.
24. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Bio 2006; 7: 952-8.
25. Shiio Y, Aebersold R. Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nature protocols 2006; 1: 139-45.
26. Pesavento JJ, Mizzen CA, Kelleher NL. Quantitative analysis of modified proteins and their positional isomers by tandem mass spectrometry: human histone H4. Analytical chemistry 2006; 78: 4271-80.
27. Singh P, Cho J, Tsai SY, Rivas GE, Larson GP, Szabo PE. Coordinated allele-specific histone acetylation at the differentially methylated regions of imprinted genes. Nucleic acids Res 2010; 38: 7974-90.
28. Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics 2009; 10: 143.
29. Martinato F, Cesaroni M, Amati B, Guccione E. Analysis of Mycinduced histone modifications on target chromatin. PloS one 2008; 3: e3650.
30. Achour M, Fuhrmann G, Alhosin M, et al. UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activity. Biochemical Biophys Res Communications 2009; 390: 523-8.
31. Vlaicu SI, Tegla CA, Cudrici CD, et al. Epigenetic modifications induced by RGC-32 in colon cancer. Experimental Mol Pathol 2010; 88: 67-76.
32. Puppin C, Passon N, Lavarone E, et al. Levels of histone acetylation in thyroid tumors. Biochemical Biophys Res Communications 2011; 411: 679-83.
33. Rubinek T, Shulman M, Israeli S, et al. Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treatment 2012; 133: 649-57.
34. Freberg CT, Dahl JA, Timoskainen S, Collas P. Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Molecular Biol Cell 2007; 18: 1543-53.
35. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nature Chemical Biol 2007; 3: 166-73.
36. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2007; 25: 4358-64.
37. Allahverdi A, Yang R, Korolev N, et al. The effects of histone H4 tail acetylations on cation-induced chromatin folding and selfassociation. Nucleic acids research 2011; 39: 1680-91.
38. Abbosh PH, Montgomery JS, Starkey JA, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer research 2006; 66: 5582-91.
39. Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nature reviews Molecular cell biology 2012; 13: 115-26.
40. Vollmuth F, Geyer M. Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. Angew Chem Int Ed Engl 2010; 49: 6768-72.
41. Lin H, Su X, He B. Protein Lysine Acylation and Cysteine Succination by Intermediates of Energy Metabolism. ACS chemical biology 2012.